Introduction
One of the greatest challenges of the functional annotation of the leukemia genome is the in-depth characterization of the transcription factor circuitry responsible for the regulation of cellular function in leukemic cells. Mutations and chromosomal rearrangements leading to structural abnormalities and/or aberrant expression of oncogenic transcription factor genes are some of the most prominent genetic alterations found in human leukemias. 1, 2 However, despite their importance, the specific function and downstream targets of leukemia transcription factor oncogenes are largely unknown. Gene expression profiling analysis of tumors driven by transcription factor oncogenes has played a key role in the classification and molecular characterization of these diseases. [3] [4] [5] However, these approaches do not allow distinctions to be made between primary events directly controlled by oncogenic transcription factors and secondary transcriptional changes resulting from changes in cell proliferation or differentiation. Investigating the direct transcriptional targets and the structure of the transcriptional networks controlled by major leukemia oncogenes is essential to identify relevant effector genes and pathways that could be exploited for the development of targeted therapies.
In addition to transcription factor dysregulation, epigenetic abnormalities could result in activation of oncogenic transcriptional programs and may play a major role in the pathogenesis of human leukemias and lymphomas. 6 The importance of understanding the role of epigenetic changes in hematologic tumors is highlighted by the potential therapeutic use of agents targeting aberrant DNA methylation and histone deacetylation. [7] [8] [9] [10] Mapping the leukemia epigenome, merging these data with the transcriptional program driven by leukemia transcription factor oncogenes and integrating this information with clinical and biological data will ultimately provide a comprehensive readout of the transcriptional network driving cell growth, proliferation and survival in the leukemic clone.
Gene expression-based methods for the identification of transcription factor target genes
The identification of direct target genes controlled by transcription factors based on the analysis of gene expression profiles is a daunting task. However, gene expression signatures tightly associated with the expression or activation of a transcription factor of interest can be obtained in experiments that typically involve blocking protein synthesis with cycloheximide and the analysis of a time course series. These experiments typically require a tight control of transcription factor function, which can be readily obtained by ligand stimulation or withdrawal in the case of ligand-activated transcription factors, such as the glucocorticoid and vitamin D receptors, 11, 12 and the PML-RARA acute promyelocytic leukemia fusion oncoprotein. 13 This approach has been extended to the analysis of additional transcription factors by generating fusions turning them into estrogen-activated proteins by fusion with the hormone-binding domain of the estrogen receptor. [14] [15] [16] [17] Alternatively, a loss-offunction variation of this approach can be achieved by inactivation of the transcription factor of interest by expression of a dominant negative form of the protein or by RNA interference knockdown. 18, 19 Despite the success of these approaches in the identification of relevant target genes for oncogenic transcription factors, their use has been limited by several technical caveats, including the need to express exogenous and structurally modified versions of the protein of interest and the broad biological effects of cycloheximide treatment. Moreover, candidate target genes identified with these techniques still need to be validated by methods that directly interrogate the binding and transcriptional effect of the transcription factor of interest.
Chromatin immunoprecipitation
A number of techniques to identify the direct target genes controlled by transcription factors have been developed, all of which are based on the analysis of DNA isolated by chromatin immunoprecipitation (ChIP). The ChIP method involves treating living cells with a crosslinking agentFusually formaldehydeFthat fixes DNA-binding proteins to their interacting DNA sequences in the nucleus. Chromatin-bound genomic DNA is then extracted and fragmented by physical shearing or enzymatic digestion. Next, specific DNA sequences associated with a particular protein are enriched by immunoaffinity purification using a specific antibody against the DNA-binding protein/transcription factor of interest. Immunoprecipitated DNA fragments are then assayed by PCR to determine the association of the protein under study with a limited number of known or suspected target sites.
ChIP-chip
Over the past years, the analysis of protein-DNA interactions has evolved from single-locus ChIP analysis to the analysis of DNA-binding sites at a genomic scale by combining ChIP assays with microarray analysis. 20 Because this approach combines ChIP and DNA microarrays (also referred to as chips), it has conventionally been referred to as ChIP-on-chip or ChIP-chip. ChIP-chip combines a classic ChIP protocol with DNA microarray analysis to allow the detection of protein-DNA interactions in a non-biased way and with genome-wide coverage. 21, 22 Specifically, the ChIP-purified DNA is amplified, fluorescently labeled and hybridized to DNA microarrays containing genomic DNA sequences along or in parallel with a control DNA sample corresponding to the total (nonimmunoprecipitated) genomic DNA. Array probes that correspond to the genomic-binding sites for the protein of interest are identified as those that show a significantly stronger fluorescent signal in the ChIP DNA than in the non-immunoprecipitated DNA control sample ( Figure 1 ). Using ChIP-chip, it is possible to interrogate the pattern of binding of a DNA-binding protein of interest through all nonrepetitive DNA sequences in the genome.
Although initial microarray platforms used for ChIP-chip analysis consisted of spotted arrays with PCR-amplified genomic regions spanning promoter sequences or CpG islands, 21, 23, 24 currently available commercial platforms have expanded the capacity and flexibility of this approach to include, in addition to promoter arrays, arrays analyzing the ENCODE regions of the genome, whole genome arrays and custom oligonucleotide arrays tiling specific genomic areas of interest.
Although ChIP-chip has rapidly become a well-established technology, there are still some challenges and technical limitations for this approach. Thus, most ChIP-chip protocols require a large amount of cells as starting material, which frequently limits its application to the analysis of cell lines. Some protocols have been developed to analyze small amounts of cells such as those derived from developing mouse embryos by ChIP-chip. 25 However, the requirement of large amounts of immunoprecipitated DNA demand using PCR-based amplification protocols or whole genome amplification techniques to amplify the starting material, methods which have an inherent risk of introducing some bias in the representation and relative abundance of ChIP DNA fragments. Additionally, the ChIP-chip technique is not suitable for interrogating repetitive sequences in the genome, and sophisticated bioinformatic and statistical tools are required for data analysis. [26] [27] [28] [29] [30] Finally, the requirement to perform biological replicas to address the reproducibility of the results and their independent validation in sequence-specific ChIP experiments of relevant targets of interest make ChIP-chip analysis a time consuming technique best suited to the analysis of a limited number of cell types and experimental conditions.
ChIP-seq
Early approaches aiming to sequence DNA fragments pulled down by ChIP using a variety of related protocols (ChIP-cloning, ChIP-SAGE and ChIP-PET) [31] [32] [33] have been hampered by the high cost associated with DNA sequencing. However, the recent development of massive parallel sequencing technologies and their application to the analysis of ChIP DNA sequences is rapidly expanding our capacity for the analysis of protein-DNA interactions (for a comprehensive recent review see Chi 34 ). Currently, there are three commercial platforms available, Roche (454) FLX Sequencer, Illumina Genome Analyzer and the Applied Biosystems SOLiD sequencer, with two more planning to hit the market in the next few yearsFHelicos HeliScope Single Molecule and Pacific Biosciences SMRT DNA Sequencers. Each of these platforms faces the technical challenge of high throughput parallel DNA sequencing using different approaches that reflect on the output of the data. 35 The most relevant differences among the three commercial platforms currently available are the lengths of the sequences and the amount of data produced by each of them ( Table 1 ). The current Roche (454) instrument, the GS-FLX, provides relatively long reads which average 250 bp and has a maximum throughput of 100 Mb of sequence data per run. The introduction of the new Titanium FLX technology in the fall of 2008 aims to increase the average length of the FLX platform to 400 bp and the total output of the system to 600 Mb per run. On the other side of the spectrum, the Illumina and ABI SOLiD platforms generate shorter reads (32-40 bp for the Illumina, 35 bp for SOLiD) but with a much higher number of reads, which ultimately generates 1-3 Gb of sequence data per run. Constant improvements in the SPOTLIGHT Figure 1 Chromatin immunoprecipitation (ChIP)-based approaches for the identification of protein-DNA interactions. Cells are treated with formaldehyde to crosslink proteins and DNA. After isolation, the genomic DNA is sheared by sonication. Next, specific antibodies are used to immunoprecipitate the DNA bound to the proteins of interest, the crosslink is reversed and the DNA is used directly for sequencing (ChIP-seq) or fluorescently labeled to be hybridized in a genomic microarray (ChIP-chip).
Leukemia ChIP-Chip and ChIP-seq T Palomero and A Ferrando 1237 number of reads per run and in sequence length are expected to result in expanded throughput capacity, and an upgraded version of the SOLiD platform that anticipates outputs of up to 20 Gb per run has been announced. Both the Roche (454) and the Illumina Genome Analyzer have been used successfully for the analysis of chromatin modifications and transcription factorbinding to DNA in human genomes. [36] [37] [38] [39] [40] However, the shorter reads and higher throughput provided by either Illumina or ABI SOLiD are considered to be an advantage, as they provide higher coverage and deeper resolution for the identification of binding locations across the whole genome in a single run. Still, the issue of mapping putative binding events from short sequence reads is still a challenge. Improved methods with increased throughput and mate pair library protocols, which couples the information of the two ends of the DNA molecule to enhance the fraction of molecules effectively mapped to the genome, partially address this issue.
A side-by-side comparison of ChIP-chip and ChIP-seq in the analysis of STAT1 has shown a high level of concordance between ChIP-chip and ChIP-seq data, although ChIP-seq identified a larger number of STAT1 DNA-binding sites. 37 In addition, a detailed comparison of the accuracy and performance of ChIP-chip and ChIP-seq approaches has been recently addressed in a report that highlight the advantage of using ChIP-chip as stepping stone toward comprehensive ChIP-seq analysis. 41 Overall, ChIP-seq approaches require less DNA than ChIP-on-chip and offer improved statistical robustness compared with ChIP-chip analysis. In addition, ChIP-seq has the potential to analyze binding throught the whole genome, including repetitive sequences. However, the high cost of ChIP-seq experiments and the intrinsic difficulties of analyzing the enormous data output generated still limit its application.
Identification of transcription factor-binding sites
Initial studies aiming to identify the sequence motifs recognized by transcription factor proteins relied mostly on the analysis of short DNA sequences isolated from oligonucleotide libraries in cell-free assays by capture/affinity purification using the transcription factor of interest as bait. The data generated by ChIP-chip and ChIP-seq experiments identifies a broad range of transcription factor DNA-binding events in the cell nucleus and facilitates the study of regulatory motifs recognized by transcription factors in the cell.
In silico computational approaches for the prediction of transcription factor-binding sites can be divided into pattern matching and pattern detection strategies. Pattern matching methods use previous knowledge on the DNA sequences recognized by a transcription factor, which is represented by consensus sequences or more accurately as weight matrices, to identify the regulatory motifs recognized by this particular DNAbinding protein in a given sequence. A caveat of these methods is that they rely on the accuracy of previously described consensus sequences, which in most cases had been identified through in vitro approaches, such as casting experiments. In addition, even in the context of well characterized matrices, pattern matching methods do not take into account the possible effect of other proteins in the transcriptional complex, which may redirect or facilitate the binding of the transcription factor under study to DNA sequences not represented in the consensus matrix. [42] [43] [44] In this regard, a recent study on the E2F-binding specificity confirmed the fact that only a small percentage of the regions bound in vivo by E2F factors actually contain the E2F consensus motif. 45 Pattern detection methods search for recurring and overrepresented DNA motifs in specific subsets of sequences, such as genomic regions identified by ChIP-chip or ChIP-seq, as bound by a given transcription factor. 42, 46 Pattern detection techniques can be used to identify putative DNA-binding motifs for transcription factors without previous knowledge of their DNA-binding properties and for the discovery of neighbor cooperating motifs specifically enriched in coregulated sets of genes.
Comparative analysis of gene expression profiling and ChIPchip or ChIP-seq data has shown that for multiple transcription factors, most DNA-binding sites do not seem to have a major transcriptional regulatory effect. [47] [48] [49] [50] Thus, the correct interpretation of ChIP-chip and ChIP-seq data requires that these studies are combined with expression profiling analysis in the context of experiments modulating the expression or activity of the transcription factor under study. A plausible explanation for the discrepancy between transcription factor location (DNAbinding data) and transcriptional regulation is that DNA binding by a transcription factor may not represent actual regulation in the cells analyzed, but the potential for a given locus to be regulated by a DNA-binding protein, which is only realized upon expression of temporally and/or tissue-restricted transcriptional coregulators. Alternatively, many transcription factors sites may have a redundant function with other transcriptional regulators in that promoter and contribute only to a small fraction of the transcriptional activity of that gene. Finally, DNAbinding events not associated with transcriptional regulation may reflect non-transcriptional functions of these proteins.
Applications of ChIP-chip to the study of human leukemia and lymphoma
The development of high throughput technologies for the study of DNA interactions has led to the mapping of protein-binding sites for some of the most prominent oncogenic factors in human leukemias and lymphomas and to the identification of transcriptional networks that control important biological functions associated with malignant transformation. Some relevant examples include the elucidation of transcriptional regulatory networks downstream of T-bet, 51 ,52 FOXP3 53 and RUNX1, 54 as well as the characterization of the extended transcriptional 
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Functional characterization of T-ALL transcription factor oncogenes
Aberrant expression of transcription factor oncogenes is a hallmark of T-cell acute lymphoblastic leukemia (T-ALL). T-ALL transcription factor oncogenes include members of the bHLH family, such as TAL1, TAL2, LYL1, BHLHB1 and MYC; the LIM-only domain (LMO) genes LMO1 and LMO2; the orphan homeobox genes TLX1/HOX11 and TLX2/HOX11L2, members of the HOXA gene paralog group, including HOXA9 and HOXA10; MYB, and most prominently, the frequently mutated NOTCH1 gene. 2, 56, 57 The TAL1 gene in chromosome band 1p32 plays an essential role in the generation of early hematopoietic progenitors and in the development of erythroid and megakaryocytic cell lineages. 58 Aberrant expression of TAL1 is present in over 60% of T-ALL cases 2, 59 and its oncogenic potential is illustrated by the induction of T-cell lymphoblastic tumors in transgenic mice. 60, 61 In T-ALL cells, TAL1 forms primarily inactive transcriptional complexes that contain the class I basic helixloop-helix (bHLH) proteins, E2A and HEB, suggesting that the oncogenic activity of TAL1 results from decreased expression of E2A/HEB target genes. 62 The regulatory circuitry controlled by TAL1 in T-ALL has been analyzed in a study that integrated information from ChIP-chip analysis, gene expression profiling of primary T-ALL samples and microarray expression analysis of T-ALL cells in which TAL1 was inactivated by RNA interference. 18 This analysis uncovered a dual role for TAL1 as repressor or activator of direct target genes. Importantly, a transcriptional activation function for TAL1 was present in genes whose promoters were also bound by E2A and HEB, thus challenging the existing hypothesis that TAL1 works primarily as a repressor of E2A/HEB transcriptional complexes. Notably, a number of TAL1 target genes identified in this work were specifically associated with the expression of this transcription factor in human primary leukemias. 18 Activating mutations in the NOTCH1 gene are the most prominent genetic abnormality in T-ALL, and inhibition of NOTCH1 activation with g-secretase inhibitors has been proposed as a targeted therapy in this disease. Gene expression analysis of T-ALL cell lines treated with a small molecule gsecretase inhibitor and ChIP-on-chip analysis of NOTCH1 in T-ALL cells showed that NOTCH1 binds to and regulates the expression of multiple genes in biosynthetic pathways, including genes involved in nucleotide metabolism, amino-acid biosynthesis, ribosome biogenesis and protein translation. 63 Moreover, this study showed that NOTCH1 directly controls c-MYC expression, so that NOTCH1 and c-MYC are integrated in an oncogenic feed-forward loop transcriptional network promoting leukemic cell growth. 63 In agreement with this model, reverse engineering of NOTCH1 and c-MYC regulatory networks using gene expression profiles from primary T-ALL samples showed that NOTCH1 and c-MYC govern two highly interconnected transcriptional programs containing numerous common target genes. 63 The analysis of the transcriptional regulatory network controlled by NOTCH1 in T-ALL has been subsequently extended by the characterization of a secondary circuitry linking NOTCH1 signaling and the activity of the PI3K-AKT pathway. 64 Functional analysis of NOTCH1 signaling in thymocyte development showed that NOTCH1 activation is required to sustain cell metabolism and the activity of the PI3K-AKT pathway. 65 Moreover, inhibition of oncogenic NOTCH1 was followed by transcriptional upregulation of PTEN, a critical tumor suppressor gene responsible for the termination of PI3K-AKT signaling in the cell. ChIP-chip analysis of HES1, a transcriptional repressor directly controlled by NOTCH1 66 and MYC, showed binding of these transcriptional regulators to the PTEN promoter in T-ALL cells. Thus, PTEN expression is controlled downstream of NOTCH1 by a dual input circuit consisting of the repressor input provided by HES1 and activation input delivered by c-MYC, which attenuates the effect of the former. 64, 67, 68 The importance of this circuitry is highlighted by the identification of mutational loss of PTEN in T-ALL cells lines resistant to NOTCH1 inhibition. In these tumors, the NOTCH-HES1/MYC-PTEN transcriptional regulatory axis is disrupted, bypassing the requirement of NOTCH1 signaling to maintain leukemic cell growth. 64, 67, 68 Genomic analysis of transcription factor oncogene targets in B-cell lymphoma and myeloma Several studies have addressed the analysis of the direct targets and transcriptional networks controlled by c-MYC and BCL6 transcription factor oncogenes in B-cell lymphoma. Pioneer ChIP-on-chip work by the group of Bin Ren on the function of c-MYC in Burkitt lymphoma cells showed that MYC binds to a surprisingly large number of gene promoters. 69 A result that has been subsequently confirmed by Zeller et al. 32 in a study that analyzed c-MYC targets by a ChIP-PET sequencing approach. These results identify c-MYC as a global transcriptional regulator suggesting that c-MYC may induce transformation of hematopoietic progenitors by regulating the activity of a large proportion of loci throughout the genome.
BCL6 is a zinc-finger transcription factor with a key role in the development of germinal center B cells and in the pathogenesis of diffuse large B-cell lymphoma. 70 ChIP-chip analysis of BCL6 in diffuse large B-cell lymphoma cells was used to define a signature of target genes distinguishing diffuse large B-cell lymphoma tumors characteristically sensitive to BCL6 inhibitors. 71 A more focused approach has been implemented for the analysis of BCL6 as a transcriptional regulator of ATR, a gene whose product mediates the activation of a DNA damage response. 72 In this case, a locus-specific tiling array was used to identify regulatory sequences in the ATR gene occupied by BCL6. 72 This study, together with previous work linking the function of BCL6 and the regulation of P53 function, 73, 74 identifies the attenuation of DNA damage response as an important developmental function of BCL6, which enables cells to tolerate the physiologic occurrence of double-strand DNA breaks during the rearrangement of immunoglobulin genes in germinal center B cells.
In multiple myeloma, a transcriptional IRF4 regulatory network involving a IRF4 and c-MYC autoregulatory circuit identified using a combination of ChIP-chip and expression profiling following inactivation of IRF4 by short hairpin RNA has proven to be essential for the survival of myeloma cells. have shown that epigenetic changes may play an important role in the pathogenesis of human cancer. Moreover, molecular therapies targeting histone deacetylases and aberrant DNA methylation are under development for the treatment of different hematologic malignancies. 7 A recent study of acute myeloid and lymphoblastic leukemias analyzed the pattern of cytosine methylation and histone H3 lysine 9 acetylation by ChIP-chip, and combined these results with gene expression data. This analysis identified relevant biological pathways disregulated in these tumors which were not readily identified using gene expression profiling data alone. 76 In a related study, Kuang et al. 77 analyzed CpG island regions in leukemia cell lines and primary ALL samples and identified genes silenced by methylation in these tumors. Notably, methylation of multiple CpG islands was associated with a worse survival, 77 as had been previously suggested in studies performed on methylation on selected groups of cancer-relevant genes in ALL. 78, 79 Analysis of chromatin modifications in the context of tumors harboring MLL rearrangements is particularly relevant given the role of MLL in methylation of histone H3 at lysine 4 (H3K4); the effect of MLL fusion oncogenes in activating the expression of multiple HOX genes and the characteristic poor prognosis associated with MLL rearrangements. 8 ChIP-chip analysis of MLL has shown that this histone methylase plays a dual role in the control of gene expression functioning as both a global transcriptional regulator and as a locus-specific activator. MLL was found to bind to the proximal promoters most of actively transcribed genes, but also to very specific regions in the genome, primarily within the HOXA cluster, associated with activation of gene expression. 80 Notably, ChIP-chip analysis with an antibody against H3K43Me showed that in both instances, the regions occupied by MLL overlapped with the histone H3 trymethylation mark.
Discussion, future challenges and perspectives
The development of ChIP-chip and ChIP-seq methods has overcome some of the major technical bottlenecks for mapping transcription factor-binding sites and for the genome-wide identification of chromatin modifications. However, some of the technical limitations inherent to the ChIP technique still pose a challenge for both ChIP-chip and ChIP-seq. First, ChIP protocols typically require large numbers of cells as starting material, which hinders the application of ChIP-chip and ChIP-seq in hematopoietic progenitors and clinical specimens. However, successful analysis of histone modification after ChIP with as few as 10 5 cells has been reported. 81 Moreover, the lower DNA requirements of ChIPseq approaches compared with ChIP-chip, may facilitate the implementation of protocols adequate for the analysis of small populations of cells.
Despite the increasing robustness of ChIP-chip and ChIP-seq protocols none of these methods is exempt of false negatives, the rate of which may be affected by the relative abundance of the transcription factor analyzed, the affinity of the different binding sites, the effectiveness of the antibody in recognizing the formaldehyde-fixed protein and the possible masking effects of different cofactors recruited to the transcriptional complex. Ideally, ChIP-chip and ChIP-seq experiments should be performed in multiple replicas performed with several antibodies against the transcription factor of interest. Thus, a necessary step toward the comprehensive annotation of transcription factor-binding sites is the availability of ChIP-validated antibodies for all transcriptional regulators encoded in the mouse and human genomes.
In a side-by-side comparison, ChIP-seq requires lower amounts of immunoprecipitated DNA and has a higher sensitivity resulting in more effective detection of low affinity DNA-binding sites. In addition, as microarray design and fabrication are not required, ChIP-seq can be directly applied to the analysis of any organism.
Overall, ChIP-chip and ChIP-seq studies provide a snapshot of the transcriptional machinery in a particular cell type at a given time. As ChIP-chip and ChIP-seq methods evolve, it will be possible to address studies aiming to analyze dynamic changes in promoter occupancy, binding of cofactors and chromatin modifications in response to different stimuli. However, the development of specific computational tools required for the integration and analysis of the vast amounts of data obtained from these high throughput techniques is probably the most relevant challenge in our way to understand the structure of global transcriptional networks in normal and malignant hematopoietic cells. 82 
